Core Viewpoint - The article emphasizes the increasing difficulty of IPOs and the heightened regulatory scrutiny, highlighting the importance of meticulous attention to details in processes such as R&D expense allocation, confirmation letters, and site visits [1]. Group 1: R&D Expense Practical Points - R&D project initiation should align with the company's strategic direction, technology trends, and R&D capabilities, with collective discussions and documentation of the process [4]. - Personnel recognition for R&D should be based on working hours or end-of-term positions, ensuring that part-time personnel's contributions are reflected in year-end bonuses [4]. - R&D material input evaluation requires reasonable verification in the absence of a BOM (Bill of Materials) [4]. - Accounting treatment for R&D expenses should be recognized before sales orders are signed, with costs transferred to inventory afterward [4][5]. Group 2: Confirmation Letter Practical Points - The selection of confirmation samples should cover significant clients/suppliers and special transaction modes, with a focus on the reporting period and audit duration [12]. - Confirmation letter content must be complete, including accounts receivable balances, revenue amounts, and contract execution progress [9]. - Address verification for confirmation letters should include comparisons with business registration addresses and actual operating locations [9]. Group 3: Site Visit Practical Points - Site visit planning should include objectives, target subjects, and timing, ensuring comprehensive background information collection [15]. - The identity of reception personnel must be verified, and evidence such as inventory serial numbers should be documented during warehouse checks [15]. - Data analysis from site visits should ensure consistency with client records and transaction data, addressing any discrepancies [15].

Core Viewpoint - The article emphasizes the increasing difficulty of IPOs and the heightened regulatory scrutiny, highlighting the importance of meticulous attention to details in processes such as R&D expense allocation, confirmation letters, and site visits [1]. Group 1: R&D Expense Practical Points - Key points for R&D project initiation include aligning with company strategy, technology trends, and ensuring internal controls are documented [5]. - R&D personnel and hours must be accurately recognized, with special attention to part-time staff contributions reflected in year-end bonuses [5]. - Material input assessments require validation when no BOM (Bill of Materials) is available, and the tracking of R&D samples must be clearly documented [5][16]. Group 2: Confirmation Letter Practical Points - Sample selection for confirmation letters should cover significant amounts, long aging, frequent transactions, and related party transactions [6]. - The content of confirmation letters must be complete, including accounts receivable balances and contract execution progress [6]. - Address verification for recipients is crucial, ensuring that the recipient is a financial or business leader and their identity is confirmed [6][14]. Group 3: Site Visit Practical Points - A site visit plan should be established, including the purpose, target, and timing of the visit [10]. - Background information must be collected prior to the visit, including public and specific transaction information [10]. - During the visit, the identity of reception personnel must be verified, and inventory checks should include photographing serial numbers and production dates [10][11]. Group 4: Course Overview - The course titled "IPO Verification of R&D Expenses, Confirmation Letters, and Site Visit Practices (2025)" will delve into regulatory requirements and practical strategies to navigate the verification process effectively [11][12]. - It will cover the importance of R&D expenses, confirmation letters, and site visits, along with recent regulatory case analyses [12]. - The course will also provide detailed insights into practical points and considerations for each area, ensuring compliance and risk avoidance [17].